PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer
Low PSA at 24 weeks predicts longer survival in prostate cancer
This post-hoc analysis of five phase 3 trials in 7129 patients with prostate cancer found that 96-month overall survival varied by metastati…
Men with prostate cancer who hit a PSA level of 0.2 ng/mL or less within 24 weeks of starting treatment are far more likely to survive at le…
In male osteoporosis, anabolic therapies improved lumbar spine and hip BMD more than antiresorptives at 12 months
Men Get Osteoporosis Too — and Now We Know Which Drugs Win
This Bayesian network meta-analysis evaluated antiresorptive and anabolic pharmacological interventions in men with osteoporosis.
A new analysis of 18 clinical trials finds that bone-building drugs may outperform bone-preserving drugs for men with osteoporosis, especial…